NCT06335355View on ClinicalTrials.gov

A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

401

Participants

Timeline

Start Date

March 31, 2024

Primary Completion Date

October 31, 2028

Study Completion Date

October 31, 2030

Conditions
Non-squamous Non-small Cell Lung Cancer
Interventions
DRUG

Adebrelimab + SHR-8068 + Pemetrexed + Carboplatin

Adebrelimab,1200mg; SHR-8068, 1.0 mg/kg; Pemetrexed, 500mg/m2; Carboplatin, AUC 5 mg/mL/min

DRUG

Camrelizumab + Pemetrexed + Carboplatin

Camrelizumab,200mg;Pemetrexed, 500mg/m2; Carboplatin, AUC 5 mg/mL/min

DRUG

Adebrelimab + Pemetrexed + Carboplatin

Adebrelimab,1200mg; Pemetrexed, 500mg/m2; Carboplatin, AUC 5 mg/mL/min

Trial Locations (1)

250117

Affiliated Tumor Hospital of Shandong First Medical University, Jinan

All Listed Sponsors
lead

Shanghai Shengdi Pharmaceutical Co., Ltd

INDUSTRY

NCT06335355 - A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients | Biotech Hunter | Biotech Hunter